TABFAT: Tirzepatide and Brown Adipose Tissue Activation (ENDO 2026)
TL;DR: TABFAT trial (ENDO 2026, n=34) found tirzepatide raised brown-fat PET/CT activity 41%→65% in 24 weeks, independent of weight loss.
What is the TABFAT trial?
TABFAT (Tirzepatide Brown and Beige Adipose Tissue Activation) is a randomised, placebo-controlled, investigator-initiated clinical trial registered as NCT06893211. It enrolled 34 premenopausal women with obesity (median age 39, median BMI 36.9 kg/m²), randomised to once-weekly tirzepatide (mean dose 8.8 mg) or placebo for 24 weeks, with brown and beige adipose tissue activity measured before and after treatment.[1]
Results were presented on 15 June 2026 by Dr Rok Herman, a resident at the University Medical Center Ljubljana, Slovenia, at ENDO 2026 — the Endocrine Society's 108th annual meeting, held 13–16 June 2026 in Chicago.[2] The trial's rationale and protocol were separately published in the peer-reviewed journal Trials.[3]
The question TABFAT was designed to answer is mechanistic, not therapeutic: does a GIP/GLP-1 dual receptor agonist change how the body burns energy through brown adipose tissue — a metabolically active fat depot that generates heat and consumes calories — independently of appetite suppression and weight loss?
What is brown adipose tissue and why does it matter for GIP/GLP-1 receptor research?
Brown adipose tissue (BAT) is a specialised fat depot, distinct from the white adipose tissue that stores energy. Rich in mitochondria and the protein UCP1 (uncoupling protein 1), BAT dissipates energy as heat rather than storing it — a process called non-shivering thermogenesis. In adult humans it is concentrated in supraclavicular and paravertebral regions and is most reliably detected by cold-stimulated 18F-FDG PET/CT imaging, since cold exposure activates BAT glucose uptake.
"Beige" adipocytes are a related cell type that can appear within white fat depots under certain stimuli, taking on some thermogenic characteristics of brown fat — a process termed browning. Both are research targets in metabolic pharmacology because, in animal models, receptor pathways that raise energy expenditure via thermogenesis are mechanistically distinct from pathways that primarily suppress appetite.[4]
Retatrutide's glucagon receptor (GCGR) component has separately been studied for an energy-expenditure effect distinct from its GLP-1/GIP-driven appetite signalling.[4] TABFAT asks a parallel question for tirzepatide, a two-receptor (GIP/GLP-1) agonist without glucagon receptor activity: is GIP and/or GLP-1 receptor engagement alone sufficient to activate brown fat in humans?
What did TABFAT report at ENDO 2026?
Design: Randomised, double-blind, placebo-controlled trial in 34 premenopausal women with obesity, once-weekly tirzepatide (mean dose 8.8 mg) vs placebo for 24 weeks. Imaging: cold-stimulated 18F-FDG PET/CT, thermoneutral MRI, and cold-stimulated infrared thermography at baseline and week 24.
Key result: BAT activity, detected by FDG-PET/CT, rose from 41.2% of participants at baseline to 64.7% at 24 weeks in the tirzepatide group, with no comparable change in the placebo group (P=.005). MRI-based measurement of supraclavicular BAT fat fraction showed reductions consistent with the PET/CT activation signal.[1]
Secondary observation: Median body-weight reduction was 13.5% in the tirzepatide arm. Resting energy expenditure (measured by indirect calorimetry) was similar between groups overall, with a numerically larger decrease seen in tirzepatide-treated participants who did not show BAT activation, though this comparison did not reach statistical significance (P=.3).
Important note: This is human clinical trial data from a conference presentation, not preclinical animal data, and has not yet appeared as a full peer-reviewed results paper. Small sample size (n=34) and an all-female, premenopausal cohort limit generalisability. Results in this population do not necessarily predict outcomes in other populations or in vitro model systems, and vice versa.
Source: Endocrine Society press release, ENDO 2026 · Trial registration: clinicaltrials.gov/NCT06893211
Is the brown-fat effect independent of weight loss — what does that suggest mechanistically?
The detail researchers flagged as most mechanistically interesting is that BAT activation did not correlate with how much weight a given participant lost. In a purely appetite-suppression model of GLP-1-class action, thermogenic tissue changes might be expected to track body-composition change — more weight lost, more adaptive change in fat depots. TABFAT's data pointed away from that simple relationship.[2]
That dissociation is consistent with a hypothesis under active study across the GLP-1 class: that receptor engagement in peripheral tissue — adipose tissue itself expresses GIP receptors — can drive local thermogenic gene programmes directly, in parallel with, rather than solely as a downstream consequence of, hypothalamic appetite signalling and calorie restriction.[4] Distinguishing a direct receptor-mediated thermogenic pathway from an indirect, weight-loss-mediated one is exactly the kind of mechanistic question a small, imaging-intensive RCT like TABFAT is designed to probe, even though it cannot fully resolve causality in a 34-person, 24-week study.
What preclinical evidence supports a GIP/GLP-1-receptor-thermogenesis link?
TABFAT's human imaging findings sit alongside separately published rodent-model data reporting upregulation of thermogenic markers Ucp1, Dio2 and Ppargc1a, plus the batokines Bmp8b and Cxcl14, alongside increases in mitochondrial proteins SDHB, COXI and TOM20.[5]
Critically, these changes were not reproduced in pair-fed control animals matched for the same degree of calorie restriction — a design feature meant to separate a receptor-driven thermogenic effect from a generic consequence of eating less. That preclinical separation mirrors TABFAT's human weight-independence finding: the thermogenic signal looks like more than a downstream artefact of appetite suppression.[5]
GIP receptor (GIPR)
Expressed directly in adipose tissue, including brown and beige depots; implicated in adipocyte thermogenic gene regulation independent of insulin secretion.
GLP-1 receptor (GLP-1R)
Primarily associated with satiety and insulin potentiation; central GLP-1R signalling has also been linked to sympathetic outflow to brown fat in rodent studies.
How does this compare with retatrutide's mechanism?
Retatrutide (LY3437943) adds a third receptor — the glucagon receptor (GCGR) — on top of the GIP/GLP-1 axis that tirzepatide engages. GCGR is expressed predominantly in the liver, and glucagon receptor agonism has its own, separately studied preclinical link to energy expenditure and thermogenesis, distinct from the adipose-GIPR pathway TABFAT investigates.[4] The two lines of evidence — GIPR-mediated brown fat activation with tirzepatide, and GCGR-mediated energy expenditure with retatrutide — represent two mechanistically distinct routes by which the GLP-1 receptor agonist class is being studied for effects beyond simple appetite suppression.
| Compound | Receptors | Thermogenesis-linked receptor | Human BAT/energy-expenditure evidence |
|---|---|---|---|
| Tirzepatide | GLP-1R + GIPR | GIPR (adipose-expressed) | TABFAT RCT, ENDO 2026 (n=34) |
| Retatrutide | GLP-1R + GIPR + GCGR | GCGR (hepatic, energy expenditure) | Preclinical & Phase 3 cardiometabolic secondary endpoints[6] |
| Semaglutide | GLP-1R only | Not a primary target | Limited direct BAT-activation data |
Table for contextual research reference only. Cross-compound comparisons are confounded by different trial populations, doses and durations.
Research compounds available for GIP/GLP-1 receptor studies
Researchers studying incretin receptor pharmacology, adipose-tissue thermogenesis, or multi-receptor agonism have access to the following HPLC-verified research reagents through Velox Peptides, for use strictly as in vitro laboratory materials:
Retatrutide and tirzepatide are supplied as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
For further background on the incretin receptor mechanisms discussed here, see:
- Tirzepatide research overview — dual-agonist mechanism and receptor pharmacology summary
- Retatrutide: mechanism of action — how the GLP-1/GIP/glucagon axis is engaged, including the glucagon receptor's proposed energy-expenditure role
- Is retatrutide a GLP-1? — receptor class taxonomy and mechanistic distinctions across the incretin agonist family
References
- Herman R, et al. TABFAT: Effect of Tirzepatide-Induced Weight Loss on Brown and Beige Adipose Tissue Activation in Women with Obesity. Presented at: ENDO 2026, the Endocrine Society's 108th Annual Meeting; 13–16 June 2026; Chicago, IL. Trial registration: NCT06893211
- Endocrine Society. Tirzepatide may change how the body uses energy. Press release, ENDO 2026, 15 June 2026. endocrine.org
- Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial. Trials, 2025. PMID: 40847412. DOI: 10.1186/s13063-025-09045-9
- Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target. Peptides / ScienceDirect, January 2026. sciencedirect.com
- Tirzepatide induces a thermogenic-like amino acid signature and mitochondrial changes in brown adipose tissue. PMC (preclinical rodent model). pmc.ncbi.nlm.nih.gov
- Eli Lilly. Retatrutide cardiometabolic secondary endpoints, TRIUMPH-1 & TRANSCEND-T2D-1. Presented at ADA 86th Scientific Sessions, 6 June 2026. See Velox Peptides summary.
Frequently Asked Questions
What is the TABFAT trial?
TABFAT (Tirzepatide Brown and Beige Adipose Tissue Activation) is a randomised, placebo-controlled, investigator-initiated clinical trial (NCT06893211) in 34 premenopausal women with obesity, testing whether once-weekly tirzepatide changes brown and beige adipose tissue activity over 24 weeks. Results were presented by Dr Rok Herman (University Medical Center Ljubljana, Slovenia) at ENDO 2026, the Endocrine Society's annual meeting, in Chicago (13–16 June 2026).
What did TABFAT find about tirzepatide and brown fat?
Cold-stimulated FDG-PET/CT detected brown adipose tissue activity in 41.2% of participants at baseline, rising to 64.7% after 24 weeks of tirzepatide, with no comparable change in the placebo group (P=.005). Thermoneutral MRI of supraclavicular fat fraction showed changes consistent with the PET/CT findings. This is published human clinical trial data reported here for scientific reference only, not a claim about any Velox Peptides research reagent.
Was the brown-fat effect independent of weight loss?
According to the ENDO 2026 presentation, brown adipose tissue activation did not correlate with the degree of body-weight reduction (median weight loss was 13.5% in the tirzepatide arm), suggesting the thermogenic tissue signal reflects a receptor-mediated pathway distinct from appetite-driven weight change. This is a mechanistic research observation, not a claim about therapeutic outcomes.
What preclinical mechanism supports GIP/GLP-1-receptor-driven thermogenesis?
Separately published preclinical work in rodent brown adipose tissue models reported that tirzepatide upregulates thermogenic markers including Ucp1, Dio2 and Ppargc1a, along with batokines Bmp8b and Cxcl14, alongside increases in mitochondrial proteins SDHB, COXI and TOM20 — effects not reproduced in pair-fed control animals, indicating a receptor-mediated rather than purely calorie-restriction-driven mechanism.
Is tirzepatide available for research use?
Yes. Velox Peptides supplies tirzepatide as an HPLC-verified (≥99% purity) lyophilised research reagent for in vitro laboratory use only. It is not licensed as a medicine through Velox Peptides and is not supplied for human or veterinary use. Licensed pharmaceutical tirzepatide (Mounjaro, Zepbound) is a separate, MHRA/FDA-approved product manufactured by Eli Lilly and is not sold by Velox Peptides.